微型RNA市场－全球产业规模、份额、趋势、机会及预测（按产品/服务、应用、最终用户、地区和竞争对手划分），2021-2031年

全球微型RNA市场预计将从2025年的17.2亿美元成长到2031年的32.4亿美元，复合年增长率为11.13%。

微型RNA）作为小型非编码RNA分子，透过抑制翻译或标靶降解传讯RNA）在基因表现调控中发挥至关重要的作用。该市场的成长主要受慢性病发病率上升以及精准生物标记在早期诊断中的重要性所驱动。基因组技术融入临床工作流程以实现精准的疾病分析，进一步推动了这一趋势。美国癌症协会预测，到2024年美国将新增2,001,140例癌症病例，凸显了微型RNA分析所提供的先进诊断能力的重要性，也说明了该领域的迫切性。

市场成长的主要障碍在于缺乏标准化的通讯协定製备和检测方案。 RNA天然的不稳定性，加上不同检测平台之间的技术差异，常导致数据重复性问题。这种不一致使得广泛临床应用所需的监管检验流程变得复杂，从而对市场扩张构成重大阻碍。

市场驱动因素

全球癌症和慢性疾病的日益普及是推动全球微型RNA市场发展的主要动力，也微型RNA产生了对能够早期检测和疾病管理的先进诊断工具的强劲需求。 microRNA因其在生物体液中的稳定性以及在病理条件下特异性表达模式而备受重视，使其成为液态生物检体应用的理想候选者。恶性肿瘤负担的不断加重进一步加剧了这种需求。例如，世界卫生组织（WHO）在2024年2月报告称，肺癌将成为全球最常见的癌症，预计新增病例将达250万例左右。如此高的发生率迫切需要采用微型RNA谱分析来解析复杂的疾病机制，以实现及时有效的治疗性介入。

同时，加速推进的临床开发和策略联盟正在验证基于微型RNA治疗方法的疗效，重塑市场格局。製药公司正积极投资前景广阔的资产，透过收购和合作拓展其在心血管和代谢疾病领域的产品组合。这一趋势的一个显着例证是，诺和诺德在2024年3月达成协议，将以高达10.25亿欧元的价格收购Cardiol Pharmaceuticals，以获得一种用于治疗心臟衰竭的领先RNA标靶化合物。这一财务动能与临床进展相辅相成。 2024年3月，Regulus Therapeutics公布了其RGLS8429 1b期研究的积极顶线数据，显示肾臟疾病生物标记显着改善，并标誌着市场正朝着商业性可行的治疗方案迈进。

市场挑战

全球微型RNA市场面临的主要障碍之一是样本製备和检测通讯协定缺乏标准化。由于RNA本身的不稳定性，即使分离和处理技术上的微小差异也会导致不同实验室间数据出现显着差异。这种技术上的不一致造成了信任度的缺失，一项研究中发现的生物标记谱往往无法在后续研究中重复验证。由此导致的无法产生可重复数据，使得监管机构要求的检验流程复杂化，并延缓了基于微型RNA的新型诊断工具的核准和商业化进程。

这种差异性对临床工作流程有重大影响，因为不一致的检测方法无法可靠地扩展到广泛的临床应用，直接抑制了市场信心和应用。产业对检查室准确性的分析从数量上凸显了这个问题的严重性：根据美国临床实验室医学学会 (ASCL) 的数据，到 2024 年，检测前误差将占所有检测误差的约 43% 至 75%。基础检测阶段如此高的错误率凸显了监管机构为何对核准微型RNA诊断保持谨慎，最终抑制了该领域的收入成长。

市场趋势

将人工智慧 (AI) 应用于微型RNA模式分析正在革新该领域，克服了以往阻碍生物标记发现的复杂结构预测难题。先进的深度学习模型现在能够精确模拟 RNA 分子与细胞标靶之间复杂的三维相互作用，从而加速有效候选疗法的识别。 Google DeepMind 于 2024 年 5 月发布了 AlphaFold 3，这是该领域的一项重大突破。 AlphaFold 3 预测蛋白质-DNA-RNA 交互作用的准确率比现有方法高出至少 50%。运算能力的飞跃将使研究人员能够更有效地绘製微型RNA调控网络，显着缩短早期标靶检验所需的时间。

同时，脂质奈米颗粒 (LNP) 和 GalNAc（N-乙酰葡萄糖胺）递送系统的创新正在解决将 RNA 有效载荷递送至肝臟以外组织的关键挑战。虽然传统载体主要局限于肝臟蓄积，但新一代平台正被设计成具有选择性器官标靶化能力，能够到达肺和脾臟等器官。这项技术进步正得到定向投资的积极支持。例如，据 ReCode Therapeutics 公司称，囊肿纤维化基金会于 2024 年 11 月同意投资高达 1500 万美元，以支持该公司开髮用于肺细胞基因修復的组织特异性脂质奈米颗粒。此类递送结构的进步对于将微型RNA疗法的临床效用从代谢性疾病扩展到呼吸系统和全身性疾病至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球微型RNA市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务分类（产品、消耗品、服务）
  • 依应用领域（癌症、感染疾病、免疫系统疾病、心血管疾病、神经系统疾病等）
  • 依最终用户划分（生物技术/製药公司、学术/政府研究机构、其他最终用户）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美微型RNA市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲微型RNA市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区微型RNA市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲微型RNA市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲微型RNA市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球微型RNA市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• Horizon Discovery Ltd.
• OriGene Technologies, Inc.
• QIAGEN
• GeneCopoeia, Inc.
• Merck KGaA
• Miltenyi Biotec
• Sistemic Scotland Limited
• SeqMatic LLC
• Biodynamics Laboratory Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global MicroRNA market is projected to expand from USD 1.72 Billion in 2025 to USD 3.24 Billion by 2031, reflecting a compound annual growth rate of 11.13%. Functioning as small non-coding RNA molecules, microRNAs are essential for regulating gene expression by either suppressing translation or targeting messenger RNA for degradation. The market is primarily propelled by the rising incidence of chronic diseases and the critical need for precise biomarkers to facilitate early diagnosis, a trend further supported by the incorporation of genomic technologies into clinical workflows for accurate disease profiling. Highlighting the urgency driving this sector, the American Cancer Society projected that 2,001,140 new cancer cases would occur in the United States in 2024, emphasizing the vital necessity for the advanced diagnostic capabilities offered by microRNA analysis.

A major obstacle hindering market growth is the absence of standardized protocols for sample preparation and detection. The natural instability of RNA, coupled with technical variations across different assay platforms, frequently results in issues with data reproducibility. This inconsistency complicates the regulatory validation processes required for widespread clinical adoption, creating significant barriers to market expansion.

Market Driver

The increasing global prevalence of cancer and chronic diseases acts as a primary engine for the Global MicroRNA market, creating a strong demand for advanced diagnostic tools capable of early detection and disease management. MicroRNAs are increasingly valued for their stability in biofluids and their specific expression patterns during pathological states, making them excellent candidates for liquid biopsy applications. This need is amplified by the growing burden of malignancies; for instance, the World Health Organization reported in February 2024 that lung cancer remained the most common cancer globally, with approximately 2.5 million new cases. Such high incidence rates necessitate the urgent adoption of microRNA profiling to decode complex disease mechanisms and enable timely therapeutic interventions.

Simultaneously, the market landscape is being reshaped by accelerating clinical development and strategic partnerships that validate microRNA-based therapeutic modalities. Pharmaceutical companies are actively investing in promising assets to broaden their cardiovascular and metabolic portfolios through acquisitions and collaborative agreements. A prominent example of this trend involves Novo Nordisk, which agreed in March 2024 to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros to secure a leading RNA-targeting compound for heart failure. This financial momentum is matched by clinical progress, as evidenced by Regulus Therapeutics in March 2024, when positive topline data from its Phase 1b trial for RGLS8429 showed distinct improvements in kidney disease biomarkers, signaling the market's progression toward commercially viable therapeutic solutions.

Market Challenge

The principal barrier restricting the Global MicroRNA market is the critical lack of standardization in sample preparation and detection protocols. Due to the inherent instability of RNA, even slight deviations in isolation or handling techniques can lead to substantial data discrepancies between laboratories. This technical inconsistency creates a reliability gap, where biomarker profiles identified in one study often fail to replicate in subsequent research. Consequently, the inability to produce reproducible data complicates the validation process required by regulatory bodies, thereby delaying the approval and commercialization of new microRNA-based diagnostic tools.

This variability has a significant impact on clinical workflows, as assays lacking uniformity cannot be reliably scaled for widespread medical use, which directly suppresses market confidence and adoption rates. The severity of this issue is quantitatively highlighted by industry analysis regarding laboratory precision; according to the Association for Diagnostics & Laboratory Medicine, in 2024, preanalytical errors were responsible for approximately 43% to 75% of all laboratory errors. Such high error rates in the foundational stages of testing underscore why regulatory agencies remain hesitant to approve microRNA diagnostics, ultimately stalling the sector's revenue growth.

Market Trends

The sector is undergoing a fundamental shift due to the integration of Artificial Intelligence for microRNA pattern analysis, which is resolving complex structural prediction challenges that previously hindered biomarker discovery. Advanced deep learning models are now capable of modeling the intricate three-dimensional interactions between RNA molecules and cellular targets with high precision, thereby accelerating the identification of viable therapeutic candidates. A major advancement in this domain was established when, according to Google DeepMind, in May 2024, the company released AlphaFold 3, which predicts the interactions of proteins with DNA and RNA with at least a 50% improvement in accuracy compared to existing methods. This leap in computational capability allows researchers to map microRNA regulatory networks more effectively, significantly reducing the time required for early-stage target validation.

Simultaneously, innovation in Lipid Nanoparticle and GalNAc delivery systems is addressing the critical bottleneck of delivering RNA payloads to extra-hepatic tissues. While earlier carriers were predominantly limited to liver accumulation, next-generation platforms are being engineered with selective organ targeting capabilities to reach organs such as the lungs and spleen. This technical evolution is actively supported by targeted investments; for instance, according to ReCode Therapeutics, in November 2024, the Cystic Fibrosis Foundation agreed to invest up to $15 million to support the company's development of tissue-specific lipid nanoparticles for gene correction in lung cells. Such advancements in delivery architecture are essential for expanding the clinical utility of microRNA therapeutics beyond metabolic disorders into respiratory and systemic conditions.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Horizon Discovery Ltd.
• OriGene Technologies, Inc.
• QIAGEN
• GeneCopoeia, Inc.
• Merck KGaA
• Miltenyi Biotec
• Sistemic Scotland Limited
• SeqMatic LLC
• Biodynamics Laboratory Inc.

Report Scope

In this report, the Global MicroRNA market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

MicroRNA market, By Product & Service

• Products
• Consumables
• Services

MicroRNA market, By Application

• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others

MicroRNA market, By End User

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Other end users

MicroRNA market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MicroRNA market.

Available Customizations:

Global MicroRNA market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global MicroRNA market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Products, Consumables, Services)
  • 5.2.2. By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others)
  • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Other end users)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America MicroRNA market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States MicroRNA market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada MicroRNA market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico MicroRNA market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe MicroRNA market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany MicroRNA market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France MicroRNA market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom MicroRNA market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy MicroRNA market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain MicroRNA market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific MicroRNA market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China MicroRNA market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India MicroRNA market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan MicroRNA market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea MicroRNA market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia MicroRNA market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa MicroRNA market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia MicroRNA market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE MicroRNA market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa MicroRNA market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America MicroRNA market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil MicroRNA market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia MicroRNA market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina MicroRNA market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global MicroRNA market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Horizon Discovery Ltd.
• 15.3. OriGene Technologies, Inc.
• 15.4. QIAGEN
• 15.5. GeneCopoeia, Inc.
• 15.6. Merck KGaA
• 15.7. Miltenyi Biotec
• 15.8. Sistemic Scotland Limited
• 15.9. SeqMatic LLC
• 15.10. Biodynamics Laboratory Inc.

16. Strategic Recommendations

17. About Us & Disclaimer